BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Whereas the BCR-ABL fusion drives the initial chronic phase of the disease, the progression of CML involves additional genomic changes which make leukemia cells resistant to TKI therapy and independent of BCR-ABL.